Business Description
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Business History
Price Overview
Last updated: Jun 27, 2026 10:55am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -6.27
Total Equity: $15.96M
Shares: 4,055,738
Total Debt: $0.00
Cash: $10.95M
EBITDA: -$20.88M
Total Debt: $0.00
Cash: $10.95M
Revenue: $0.00
Shares: 4,055,738
Revenue: $0.00
Revenue: $0.00
Revenue: $0.00
Total Equity: $15.96M
Tax Rate: 0.0%
Equity: $15.96M
Total Debt: $0.00
Cash: $10.95M
Current Liabilities: $5.13M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $15.96M
Shares: 4,055,738
Shares: 4,055,738
CapEx: -$38.11M
Shares: 4,055,738
Stock Price: $1.11
Net Income: -$25.41M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 26, 2026 7:17am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $499,000 | $3.9M | $4.0M | $4.0M | $0 |
| Gross Profit | $-499,000 | -$3.9M | -$4.0M | -$4.0M | $0 |
| Operating Expenses | $36.2M | $36.1M | $31.5M | $22.4M | $24.8M |
| Operating Income | -$36.2M | -$36.1M | -$31.5M | -$26.4M | -$24.8M |
| Net Income | -$39.2M | -$38.3M | -$32.4M | -$26.9M | -$25.4M |
| EBITDA | -$34.7M | -$31.7M | -$27.6M | -$22.2M | -$20.9M |
| EPS | $-28.80 | $-26.70 | $-21.90 | $-13.50 | $-6.27 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 7:17am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $36.1M | $22.7M | $4.1M | $4.7M | $11.0M |
| Total Current Assets | $45.3M | $25.4M | $6.9M | $6.1M | $11.6M |
| Total Assets | $75.9M | $50.5M | $30.5M | $27.0M | $28.2M |
| Current Liabilities | $3.9M | $4.7M | $5.6M | $4.6M | $5.1M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $19.3M | $18.4M | $17.3M | $14.1M | $12.2M |
| Total Equity | $56.5M | $32.2M | $13.2M | $12.9M | $16.0M |
| Retained Earnings | -$418.2M | -$454.9M | -$487.1M | -$514.0M | -$539.4M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 7:17am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$18.8M | -$18.2M | -$22.8M | -$18.8M | -$17.1B |
| Capital Expenditure | -$9.0M | $-660,633 | $-372,262 | $-94,875 | -$38.1M |
| Free Cash Flow | -$27.8M | -$18.9M | -$23.2M | -$18.9M | -$17.2B |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $20.6M | -$13.4M | -$18.5M | $592,438 | $6.2B |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:07am (47m ago)| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$260,000 $260,000 – $260,000
|
$9.1M $9.1M – $9.1M
|
$4.7M $4.7M – $4.7M
|
$19.0M $19.0M – $19.0M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$80.3M -$80.3M – -$80.3M
|
-$18.3M -$18.3M – -$18.3M
|
-$16.9M -$16.9M – -$16.9M
|
-$3.7M -$3.7M – -$3.7M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 7:17am (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | -678.2% | -1.9% | -0.3% | +100.0% |
| Operating Income Growth | +0.4% | +12.7% | +16.3% | +5.9% |
| Net Income Growth | +2.3% | +15.4% | +16.8% | +5.6% |
| EBITDA Growth | +8.6% | +13.2% | +19.4% | +6.0% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 5:34am (5h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-14 | KERSTEN GEERT R | P-Purchase | 300,000.00 | $1.20 | $360,000 |
| 2026-05-13 | KERSTEN GEERT R | P-Purchase | 100,000.00 | $1.19 | $119,000 |
| 2026-03-31 | TALOR EYAL | A-Award | 747.00 | $3.21 | $2,398 |
| 2026-03-31 | PRICHEP PATRICIA B | A-Award | 1,336.00 | $3.21 | $4,289 |
| 2026-03-31 | KERSTEN GEERT R | A-Award | 1,682.00 | $3.21 | $5,399 |
| 2026-01-22 | KERSTEN GEERT R | P-Purchase | 38,023.00 | $5.26 | $200,001 |
| 2025-12-31 | TALOR EYAL | A-Award | 456.00 | $5.26 | $2,399 |
| 2025-12-31 | PRICHEP PATRICIA B | A-Award | 815.00 | $5.26 | $4,287 |
| 2025-12-31 | KERSTEN GEERT R | A-Award | 998.00 | $5.26 | $5,249 |
| 2025-12-04 | KERSTEN GEERT R | P-Purchase | 8,389.00 | $5.96 | $49,998 |
| 2025-09-30 | TALOR EYAL | A-Award | 260.00 | $9.20 | $2,392 |
| 2025-09-30 | PRICHEP PATRICIA B | A-Award | 466.00 | $9.20 | $4,287 |
| 2025-09-30 | KERSTEN GEERT R | A-Award | 570.00 | $9.20 | $5,244 |
| 2025-07-28 | Watson Robert Eugene | A-Award | 4,000.00 | $8.20 | $32,800 |
| 2025-07-28 | BAILLAVOINE BRUNO JEAN-MARIE | A-Award | 4,000.00 | $8.20 | $32,800 |
| 2025-07-28 | CIPRIANO JOHN | A-Award | 7,500.00 | $8.20 | $61,500 |
| 2025-07-28 | TALOR EYAL | A-Award | 15,000.00 | $8.20 | $123,000 |
| 2025-07-28 | PRICHEP PATRICIA B | A-Award | 12,000.00 | $8.20 | $98,400 |
| 2025-07-28 | KERSTEN GEERT R | A-Award | 25,000.00 | $8.20 | $205,000 |
| 2025-07-25 | Watson Robert Eugene | P-Purchase | 2,919.00 | $6.85 | $19,995 |
Dividend History (Last 20)
Last updated: Jun 26, 2026 7:17am (1d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 1996-08-28 | $0.01 |
Narrative Economics
market-narrative step).